<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894230</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00044989</org_study_id>
    <secondary_id>Pro00045542</secondary_id>
    <nct_id>NCT01894230</nct_id>
  </id_info>
  <brief_title>Genetically Guided Statin Therapy</brief_title>
  <official_title>Genetically Guided Statin Therapy to Improve Medication Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>David Grant U.S. Air Force Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if using genetics can improve statin adherence in
      patients who should be taking statins but are not because of prior side effects. This study
      will assist physicians/providers in making a personalized health care plan for prevention of
      cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) reductase inhibitors (&quot;statins&quot;) are commonly
      prescribed to lower low density lipoprotein cholesterol (LDLc) and to prevent cardiovascular
      disease (CVD), a leading cause of morbidity and mortality. Long-term adherence to statins in
      the primary care environment is challenging; consequences of statin non-adherence include
      higher LDLc levels, hospitalizations, costs, and death due to CVD.

      Medication non-adherence is complex and multifactorial and can be associated with a number of
      factors including medication cost, complexity of medication regimen, poor provider-patient
      relationship / communication, and adverse side effects. For statins, side effects such as
      muscle aches, cramping, and pain (referred to broadly as statin-related myopathy) are a
      frequent cause of non-adherence. These symptoms are non-specific and are frequent reasons for
      stopping statin therapy, due to patient or provider concern about the possibility of
      statin-related myopathy. Many patients may be needlessly deprived of the cardiovascular
      benefits of long-term statin use.

      A genetic risk factor for statin myopathy and subsequent non-adherence has recently been
      identified. In a genome-wide association study, a genetic variant (named SLCO1B1*5) was a
      main contributor of statin myopathy. It was demonstrated that the SLCO1B1*5 variant is not
      only a predictor of myopathy, but also of premature statin discontinuation. The risk with the
      *5 allele is statin specific: greatest with simvastatin and atorvastatin use, the least with
      pravastatin or rosuvastatin. Therefore, the SLCO1B1*5 variant is common, can predict
      myopathy, subsequent non-adherence, and due to its statin-specific effects creates a novel
      research paradigm for personalizing statins to an individual's genetic profile. Carriers of
      the SLCO1B1*5 variant may do best on rosuvastatin, pravastatin, or fluvastatin whereas
      non-carriers may be treated with any statin.

      The objective of this study is to conduct a randomized trial comparing two strategies:

        1. genetically guided statin therapy vs.

        2. usual care (i.e., a strategy without genetics) on the effects of statin adherence and
           LDLc lowering.

      The overall hypothesis is that genetically guided statin therapy will lead to greater statin
      adherence and lower LDLc when compared to a non-guided strategy. The design of this trial
      will randomize primary care patients within Duke University Health System (DUHS) and travis
      Air Force Base (TAFB) clinics that are nonadherent to statins due to prior side-effects in an
      unblinded, 1:1 fashion, stratified by SLCO1B1*5 genotype.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 30, 2016</completion_date>
  <primary_completion_date type="Actual">April 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morisky Medication Adherence Scale (MMAS) Score</measure>
    <time_frame>3 months and 8 months</time_frame>
    <description>The Morisky Medication Adherence Scale (MMAS) is a self-reported measure of adherence, collected at baseline for general medication and at 3 and 8 months of followup for statin specific adherence. The eight-item MMAS survey will be used. This is a modified version of the original four-item MMAS capturing further aspects of adherence behavior. The survey includes 8 yes/no items that are summed to create an overall adherence score ranging from of 0 to 8, with higher scores indicating better adherence. The primary hypothesis is that the genetically guided statin therapy leads to greater adherence of statin therapy, corresponding to a higher MMAS score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDLc) at Baseline, Month 3 and Month 8</measure>
    <time_frame>Baseline, Month 3, Month 8</time_frame>
    <description>The continuous outcomes LDLc will be modeled as a linear regression with arm and baseline LDL as predictors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Possession Ratio (MPR) From Baseline to Last Patient Follow-up</measure>
    <time_frame>Baseline to Last patient follow-up in study (3 months or 8 months)</time_frame>
    <description>Medication possession ratio will be calculated based on number of statin medication refills over time from randomization to end of follow up. MPR is calculated as follows: 1.Sum of the days' supply of all statin medications is the sum of the number of pills dispensed for each statin prescription during follow up (taken from 3-month, 4-month and 8-month statin utilization review) 2.Sum of the days of follow up = date of 8-month follow up survey - date of randomization 3.MPR = #1/#2 MPR will be modeled as a linear regression with arm, genotype, and site as predictors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting New Statin Prescriptions</measure>
    <time_frame>Baseline, Month 3, Month 8</time_frame>
    <description>The number of new prescriptions is binary and will be modeled with logistic regression with arm, genotype, and site as predictors. Any variables imbalanced between arms will also be included as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score - Pain Severity at Month 3 and Month 8</measure>
    <time_frame>Month 3 and Month 8</time_frame>
    <description>Brief Pain Inventory data will be taken from 3 and 8-month follow up Patient Surveys. Pain severity and pain interference will be compared between groups. Both of these measures will be modeled as a linear regression with arm, genotype, and site as predictors. Transformations of the response may be explored depending on the distribution of the regression residuals. Baseline pain scores will also be included as a covariate to account for baseline variability.
Scores range from 0-10. Higher scores indicate higher pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score - Pain Interference at Month 3 and Month 8</measure>
    <time_frame>Month 3 and Month 8</time_frame>
    <description>Brief Pain Inventory data will be taken from 3 and 8-month follow up Patient Surveys. -Pain severity and pain interference will be compared between groups -Both of these measures will be modeled as a linear regression with arm as predictor. Baseline pain scores will also be included as a covariate to account for baseline variability.
Scores range from 0-10. Higher scores indicate higher pain interference with daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form -12 Item (SF-12) Health Survey - Physical Component (PC)</measure>
    <time_frame>Baseline, Month 3, Month 8</time_frame>
    <description>Month 3 and Month 8 SF12 scores for mental and physical health will be compared. Both of these measures will be modeled as a linear regression with arm as predictor. Baseline SF-12 scores will also be included as a covariate to account for baseline variability.
Ranges from 0 to 100, where a zero score indicates the lowest level of physical health measured by the scales and 100 indicates the highest level of physical health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form -12 Item (SF-12) Health Survey - Mental Component (MC)</measure>
    <time_frame>Baseline, Month 3, Month 8</time_frame>
    <description>Month 3 and Month 8 SF12 scores for mental and physical health will be compared. Both of these measures will be modeled as a linear regression with arm as predictor. Baseline SF-12 scores will also be included as a covariate to account for baseline variability.
Ranges from 0 to 100, where a zero score indicates the lowest level of mental health measured by the scales and 100 indicates the highest level of mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Scale Score</measure>
    <time_frame>Baseline and Month 8</time_frame>
    <description>Activity levels will be compared at the end of 8-months. Activity levels are defined by a five-level ordinal variable (0-4; higher level corresponding to higher activity). which was calculated based on survey answers. An ordinal logistic regression model will be used with arm as predictor. The assumption of proportional odds will be checked, and if it is not met, a multinomial regression model will be used. -Baseline physical activity will also be included as a covariate to account for baseline variability.
Scale score (0-4): 0 - Inactivity, 1 - Ligh-intensity activity, 2 - moderate-intensity activity, 3 - Hard-intensity activity, 5 - very hard-intensity activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beliefs About Medications (BMQ) Score at Baseline, Month 3 and Month 8</measure>
    <time_frame>Baseline, Month 3, Month 8</time_frame>
    <description>Questionnaire administered at baseline, 3 months, and 8 months
This instrument assesses beliefs regarding necessity and concerns related to disease-specific medications
The score ranges from 5 to 25 representing the sum of 5 questions. This will be modeled with linear regression including treatment as predictor. Baseline BMQ scores will also be included as a covariate to account for baseline variability.
Higher score corresponds to higher thought necessity and higher thought concerns about taking the medication. The higher the necessity score, the more the patient believed statins necessary for their health. The higher the concerns score, the more the patient was concerned about taking stains (side effects).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Genotype results plus usual care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLCO1B1*5 allele testing, results reported at randomization: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SLCO1B1*5 allele testing, results reported at end of study: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SLCO1B1*5 allele testing, results reported at randomization</intervention_name>
    <description>Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization</description>
    <arm_group_label>Genotype results plus usual care</arm_group_label>
    <other_name>genotype informed statin therapy (GIST)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SLCO1B1*5 allele testing, results reported at end of study</intervention_name>
    <description>Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study</description>
    <arm_group_label>Usual care only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic testing for SLCO1B1*5 allele</intervention_name>
    <description>Blood test for SLCO1B1*5 allele</description>
    <arm_group_label>Genotype results plus usual care</arm_group_label>
    <arm_group_label>Usual care only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current patient (defined as seen in the last year) of the Duke Primary Care at Pickett
             Road, Pickens Family Medicine Center or Travis Air Force Base

          -  Age greater than or equal to 18 years

          -  Current non-utilization of statin therapy for either of the following reasons: (a)
             Prior side effects thought to be attributed by the patient to statin use AND/OR (b)
             Physician removal of statin due to presumed associated side effects

          -  No statin use for the past 6 weeks

          -  Active email account

          -  Computer access available in order to complete on-line surveys

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Prior rhabdomyolysis, or Creatine Kinase (CK) elevation &gt; 10 times the upper limit of
             normal with any statin therapy

          -  Prior unexplained elevation in hepatic enzymes [Aspartate Aminotransferase (AST) or
             Alanine Aminotransferase (ALT) &gt; 3 times upper limit of normal] with any statin
             therapy

          -  Current daily grapefruit juice usage (on average &gt;1quart/day)

          -  Expected long term use (longer than 3 months) of the following medications known to
             interfere with statin metabolism or disposition at time of enrollment until the
             randomization is complete. However, short-term (&lt;14 days) is allowed for the duration
             of the study

          -  Participation in a drug research study in the past 30 days

          -  Previous use of 4 or more statins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak Voora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Lau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>David Grant US Air Force Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Grant US Air Force Medical Center</name>
      <address>
        <city>Travis Air Force Base</city>
        <state>California</state>
        <zip>94535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <results_first_submitted>April 24, 2017</results_first_submitted>
  <results_first_submitted_qc>June 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2017</results_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high cholesterol</keyword>
  <keyword>genetic testing</keyword>
  <keyword>medication adherence</keyword>
  <keyword>statins</keyword>
  <keyword>Adverse Effects</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eight participants that signed a consent either withdrew consent, were lost-to follow up, or were screen-failures and thus were not randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Genotype Results Plus Usual Care</title>
          <description>Genetic testing for SLCO1B1*5 allele
Reporting for SLCO1B1*5 allele at randomization
Reporting for SLCO1B1*5 allele at randomization: Reporting of genetic test results to patient and provider at randomization
Genetic testing for SLCO1B1*5 allele: Blood test for SLCO1B1*5 allele</description>
        </group>
        <group group_id="P2">
          <title>Usual Care Only</title>
          <description>Genetic testing for SLCO1B1*5 allele
Reporting for SLCO1B1*5 allele at the end of study
Reporting for SLCO1B1*5 allele at the end: Usual care recommendations provided to patient and provider at randomization. Genotyping results provided at the end of study.
Genetic testing for SLCO1B1*5 allele: Blood test for SLCO1B1*5 allele</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-adherent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genotype Results Plus Usual Care</title>
          <description>Genetic testing for SLCO1B1*5 allele
Reporting for SLCO1B1*5 allele at randomization
Reporting for SLCO1B1*5 allele at randomization: Reporting of genetic test results to patient and provider at randomization
Genetic testing for SLCO1B1*5 allele: Blood test for SLCO1B1*5 allele</description>
        </group>
        <group group_id="B2">
          <title>Usual Care Only</title>
          <description>Genetic testing for SLCO1B1*5 allele
Reporting for SLCO1B1*5 allele at the end of study
Reporting for SLCO1B1*5 allele at the end: Usual care recommendations provided to patient and provider at randomization. Genotyping results provided at the end of study.
Genetic testing for SLCO1B1*5 allele: Blood test for SLCO1B1*5 allele</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="10.2"/>
                    <measurement group_id="B2" value="62.5" spread="11.5"/>
                    <measurement group_id="B3" value="62.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morisky Medication Adherence Scale (MMAS) Score</title>
        <description>The Morisky Medication Adherence Scale (MMAS) is a self-reported measure of adherence, collected at baseline for general medication and at 3 and 8 months of followup for statin specific adherence. The eight-item MMAS survey will be used. This is a modified version of the original four-item MMAS capturing further aspects of adherence behavior. The survey includes 8 yes/no items that are summed to create an overall adherence score ranging from of 0 to 8, with higher scores indicating better adherence. The primary hypothesis is that the genetically guided statin therapy leads to greater adherence of statin therapy, corresponding to a higher MMAS score.</description>
        <time_frame>3 months and 8 months</time_frame>
        <population>Only participants who re-initiated statin use were eligible to do statin specific MMAS and included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Morisky Medication Adherence Scale (MMAS) Score</title>
          <description>The Morisky Medication Adherence Scale (MMAS) is a self-reported measure of adherence, collected at baseline for general medication and at 3 and 8 months of followup for statin specific adherence. The eight-item MMAS survey will be used. This is a modified version of the original four-item MMAS capturing further aspects of adherence behavior. The survey includes 8 yes/no items that are summed to create an overall adherence score ranging from of 0 to 8, with higher scores indicating better adherence. The primary hypothesis is that the genetically guided statin therapy leads to greater adherence of statin therapy, corresponding to a higher MMAS score.</description>
          <population>Only participants who re-initiated statin use were eligible to do statin specific MMAS and included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMAS Score 3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="1.5"/>
                    <measurement group_id="O2" value="6.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMAS Score 8 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="1.7"/>
                    <measurement group_id="O2" value="7.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3</non_inferiority_desc>
            <p_value>0.96</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.0189</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3986</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8</non_inferiority_desc>
            <p_value>0.57</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.2468</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4315</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoprotein Cholesterol (LDLc) at Baseline, Month 3 and Month 8</title>
        <description>The continuous outcomes LDLc will be modeled as a linear regression with arm and baseline LDL as predictors.</description>
        <time_frame>Baseline, Month 3, Month 8</time_frame>
        <population>All subjects with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein Cholesterol (LDLc) at Baseline, Month 3 and Month 8</title>
          <description>The continuous outcomes LDLc will be modeled as a linear regression with arm and baseline LDL as predictors.</description>
          <population>All subjects with available data were included in the analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LDLc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.7" spread="41.1"/>
                    <measurement group_id="O2" value="157.6" spread="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 LDLc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.9" spread="42"/>
                    <measurement group_id="O2" value="144.4" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 LDLc</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.6" spread="37.9"/>
                    <measurement group_id="O2" value="141" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3</non_inferiority_desc>
            <p_value>0.0482</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-11.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.68</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8</non_inferiority_desc>
            <p_value>0.12</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-9.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.333</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Possession Ratio (MPR) From Baseline to Last Patient Follow-up</title>
        <description>Medication possession ratio will be calculated based on number of statin medication refills over time from randomization to end of follow up. MPR is calculated as follows: 1.Sum of the days' supply of all statin medications is the sum of the number of pills dispensed for each statin prescription during follow up (taken from 3-month, 4-month and 8-month statin utilization review) 2.Sum of the days of follow up = date of 8-month follow up survey - date of randomization 3.MPR = #1/#2 MPR will be modeled as a linear regression with arm, genotype, and site as predictors.</description>
        <time_frame>Baseline to Last patient follow-up in study (3 months or 8 months)</time_frame>
        <population>Only subjects who re-initiated statin medication and reported statin medication refills were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Possession Ratio (MPR) From Baseline to Last Patient Follow-up</title>
          <description>Medication possession ratio will be calculated based on number of statin medication refills over time from randomization to end of follow up. MPR is calculated as follows: 1.Sum of the days' supply of all statin medications is the sum of the number of pills dispensed for each statin prescription during follow up (taken from 3-month, 4-month and 8-month statin utilization review) 2.Sum of the days of follow up = date of 8-month follow up survey - date of randomization 3.MPR = #1/#2 MPR will be modeled as a linear regression with arm, genotype, and site as predictors.</description>
          <population>Only subjects who re-initiated statin medication and reported statin medication refills were included in the analysis.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.632" spread="0.333"/>
                    <measurement group_id="O2" value="0.685" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>MPR calculated from baseline to last patient follow-up (3 months or 8 months)</non_inferiority_desc>
            <p_value>0.6692</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.091</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting New Statin Prescriptions</title>
        <description>The number of new prescriptions is binary and will be modeled with logistic regression with arm, genotype, and site as predictors. Any variables imbalanced between arms will also be included as covariates.</description>
        <time_frame>Baseline, Month 3, Month 8</time_frame>
        <population>Only subjects reporting new prescriptions were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting New Statin Prescriptions</title>
          <description>The number of new prescriptions is binary and will be modeled with logistic regression with arm, genotype, and site as predictors. Any variables imbalanced between arms will also be included as covariates.</description>
          <population>Only subjects reporting new prescriptions were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 to Month 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Baseline to Month 3</non_inferiority_desc>
            <p_value>0.0371</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>3.929</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3 to Month 8</non_inferiority_desc>
            <p_value>0.8815</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.115</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.265</ci_lower_limit>
            <ci_upper_limit>4.687</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory (BPI) Score - Pain Severity at Month 3 and Month 8</title>
        <description>Brief Pain Inventory data will be taken from 3 and 8-month follow up Patient Surveys. Pain severity and pain interference will be compared between groups. Both of these measures will be modeled as a linear regression with arm, genotype, and site as predictors. Transformations of the response may be explored depending on the distribution of the regression residuals. Baseline pain scores will also be included as a covariate to account for baseline variability.
Scores range from 0-10. Higher scores indicate higher pain severity.</description>
        <time_frame>Month 3 and Month 8</time_frame>
        <population>Only subjects that completed the Brief Pain Inventory surveys were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) Score - Pain Severity at Month 3 and Month 8</title>
          <description>Brief Pain Inventory data will be taken from 3 and 8-month follow up Patient Surveys. Pain severity and pain interference will be compared between groups. Both of these measures will be modeled as a linear regression with arm, genotype, and site as predictors. Transformations of the response may be explored depending on the distribution of the regression residuals. Baseline pain scores will also be included as a covariate to account for baseline variability.
Scores range from 0-10. Higher scores indicate higher pain severity.</description>
          <population>Only subjects that completed the Brief Pain Inventory surveys were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.608" spread="1.978"/>
                    <measurement group_id="O2" value="1.493" spread="1.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.939" spread="1.93"/>
                    <measurement group_id="O2" value="1.689" spread="2.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3</non_inferiority_desc>
            <p_value>0.5965</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.270</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8</non_inferiority_desc>
            <p_value>0.4579</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.258</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.346</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory (BPI) Score - Pain Interference at Month 3 and Month 8</title>
        <description>Brief Pain Inventory data will be taken from 3 and 8-month follow up Patient Surveys. -Pain severity and pain interference will be compared between groups -Both of these measures will be modeled as a linear regression with arm as predictor. Baseline pain scores will also be included as a covariate to account for baseline variability.
Scores range from 0-10. Higher scores indicate higher pain interference with daily activities.</description>
        <time_frame>Month 3 and Month 8</time_frame>
        <population>Only subjects that completed the Brief Pain Inventory surveys were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) Score - Pain Interference at Month 3 and Month 8</title>
          <description>Brief Pain Inventory data will be taken from 3 and 8-month follow up Patient Surveys. -Pain severity and pain interference will be compared between groups -Both of these measures will be modeled as a linear regression with arm as predictor. Baseline pain scores will also be included as a covariate to account for baseline variability.
Scores range from 0-10. Higher scores indicate higher pain interference with daily activities.</description>
          <population>Only subjects that completed the Brief Pain Inventory surveys were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.108" spread="1.141"/>
                    <measurement group_id="O2" value="1.971" spread="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.964" spread="0.894"/>
                    <measurement group_id="O2" value="1.689" spread="0.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3</non_inferiority_desc>
            <p_value>0.5477</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.163</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8</non_inferiority_desc>
            <p_value>0.0429</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.298</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.145</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form -12 Item (SF-12) Health Survey - Physical Component (PC)</title>
        <description>Month 3 and Month 8 SF12 scores for mental and physical health will be compared. Both of these measures will be modeled as a linear regression with arm as predictor. Baseline SF-12 scores will also be included as a covariate to account for baseline variability.
Ranges from 0 to 100, where a zero score indicates the lowest level of physical health measured by the scales and 100 indicates the highest level of physical health</description>
        <time_frame>Baseline, Month 3, Month 8</time_frame>
        <population>Only subjects that completed the SF-12 Health Survey were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form -12 Item (SF-12) Health Survey - Physical Component (PC)</title>
          <description>Month 3 and Month 8 SF12 scores for mental and physical health will be compared. Both of these measures will be modeled as a linear regression with arm as predictor. Baseline SF-12 scores will also be included as a covariate to account for baseline variability.
Ranges from 0 to 100, where a zero score indicates the lowest level of physical health measured by the scales and 100 indicates the highest level of physical health</description>
          <population>Only subjects that completed the SF-12 Health Survey were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.244" spread="6.554"/>
                    <measurement group_id="O2" value="41.692" spread="7.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.389" spread="6.891"/>
                    <measurement group_id="O2" value="41.566" spread="5.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.179" spread="6.754"/>
                    <measurement group_id="O2" value="41.359" spread="5.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3</non_inferiority_desc>
            <p_value>0.8106</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.881</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8</non_inferiority_desc>
            <p_value>0.5233</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.646</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.009</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form -12 Item (SF-12) Health Survey - Mental Component (MC)</title>
        <description>Month 3 and Month 8 SF12 scores for mental and physical health will be compared. Both of these measures will be modeled as a linear regression with arm as predictor. Baseline SF-12 scores will also be included as a covariate to account for baseline variability.
Ranges from 0 to 100, where a zero score indicates the lowest level of mental health measured by the scales and 100 indicates the highest level of mental health.</description>
        <time_frame>Baseline, Month 3, Month 8</time_frame>
        <population>Only subjects that completed the SF-12 Health Survey were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form -12 Item (SF-12) Health Survey - Mental Component (MC)</title>
          <description>Month 3 and Month 8 SF12 scores for mental and physical health will be compared. Both of these measures will be modeled as a linear regression with arm as predictor. Baseline SF-12 scores will also be included as a covariate to account for baseline variability.
Ranges from 0 to 100, where a zero score indicates the lowest level of mental health measured by the scales and 100 indicates the highest level of mental health.</description>
          <population>Only subjects that completed the SF-12 Health Survey were included in the analysis.</population>
          <units>units on a scale 0 to 100</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.393" spread="11.801"/>
                    <measurement group_id="O2" value="44.101" spread="12.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.835" spread="11.438"/>
                    <measurement group_id="O2" value="44.595" spread="11.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.776" spread="11.344"/>
                    <measurement group_id="O2" value="44.327" spread="11.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3</non_inferiority_desc>
            <p_value>0.6841</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.6001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.472</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8</non_inferiority_desc>
            <p_value>0.6658</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.771</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.781</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Activity Scale Score</title>
        <description>Activity levels will be compared at the end of 8-months. Activity levels are defined by a five-level ordinal variable (0-4; higher level corresponding to higher activity). which was calculated based on survey answers. An ordinal logistic regression model will be used with arm as predictor. The assumption of proportional odds will be checked, and if it is not met, a multinomial regression model will be used. -Baseline physical activity will also be included as a covariate to account for baseline variability.
Scale score (0-4): 0 - Inactivity, 1 - Ligh-intensity activity, 2 - moderate-intensity activity, 3 - Hard-intensity activity, 5 - very hard-intensity activity</description>
        <time_frame>Baseline and Month 8</time_frame>
        <population>Only subjects that completed the Physical Activity survey were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Activity Scale Score</title>
          <description>Activity levels will be compared at the end of 8-months. Activity levels are defined by a five-level ordinal variable (0-4; higher level corresponding to higher activity). which was calculated based on survey answers. An ordinal logistic regression model will be used with arm as predictor. The assumption of proportional odds will be checked, and if it is not met, a multinomial regression model will be used. -Baseline physical activity will also be included as a covariate to account for baseline variability.
Scale score (0-4): 0 - Inactivity, 1 - Ligh-intensity activity, 2 - moderate-intensity activity, 3 - Hard-intensity activity, 5 - very hard-intensity activity</description>
          <population>Only subjects that completed the Physical Activity survey were included in the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.838" spread="1.629"/>
                    <measurement group_id="O2" value="1.736" spread="0.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.923" spread="1.152"/>
                    <measurement group_id="O2" value="1.667" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8</non_inferiority_desc>
            <p_value>0.8384</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Ordinal Logistic</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.495</ci_lower_limit>
            <ci_upper_limit>2.380</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beliefs About Medications (BMQ) Score at Baseline, Month 3 and Month 8</title>
        <description>Questionnaire administered at baseline, 3 months, and 8 months
This instrument assesses beliefs regarding necessity and concerns related to disease-specific medications
The score ranges from 5 to 25 representing the sum of 5 questions. This will be modeled with linear regression including treatment as predictor. Baseline BMQ scores will also be included as a covariate to account for baseline variability.
Higher score corresponds to higher thought necessity and higher thought concerns about taking the medication. The higher the necessity score, the more the patient believed statins necessary for their health. The higher the concerns score, the more the patient was concerned about taking stains (side effects).</description>
        <time_frame>Baseline, Month 3, Month 8</time_frame>
        <population>Only subjects that completed the Beliefs About Medications questionnaire were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype Results Plus Usual Care</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at randomization</description>
          </group>
          <group group_id="O2">
            <title>Usual Care Only</title>
            <description>-Genetic testing for SLCO1B1*5 allele reported to patient and provider at the end of study</description>
          </group>
        </group_list>
        <measure>
          <title>Beliefs About Medications (BMQ) Score at Baseline, Month 3 and Month 8</title>
          <description>Questionnaire administered at baseline, 3 months, and 8 months
This instrument assesses beliefs regarding necessity and concerns related to disease-specific medications
The score ranges from 5 to 25 representing the sum of 5 questions. This will be modeled with linear regression including treatment as predictor. Baseline BMQ scores will also be included as a covariate to account for baseline variability.
Higher score corresponds to higher thought necessity and higher thought concerns about taking the medication. The higher the necessity score, the more the patient believed statins necessary for their health. The higher the concerns score, the more the patient was concerned about taking stains (side effects).</description>
          <population>Only subjects that completed the Beliefs About Medications questionnaire were included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, BMQ Necessity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.878" spread="3.49"/>
                    <measurement group_id="O2" value="13.893" spread="3.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, BMQ Necessity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.347" spread="3.75"/>
                    <measurement group_id="O2" value="13.185" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, BMQ Necessity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.148" spread="3.983"/>
                    <measurement group_id="O2" value="13.9" spread="3.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, BMQ Concerns</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.962" spread="3.345"/>
                    <measurement group_id="O2" value="16.067" spread="2.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, BMQ Concerns</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.471" spread="3.984"/>
                    <measurement group_id="O2" value="15.333" spread="3.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, BMQ Concerns</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.585" spread="4.088"/>
                    <measurement group_id="O2" value="14.593" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3 BMQ Necessity</non_inferiority_desc>
            <p_value>0.0486</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>1.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.584</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8, BMQ Necessity</non_inferiority_desc>
            <p_value>0.7235</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.248</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 3, BMQ Concerns</non_inferiority_desc>
            <p_value>0.2113</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.862</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.686</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Month 8, BMQ Concerns</non_inferiority_desc>
            <p_value>0.1739</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-1.0083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.737</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through Month 8</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Genotype Results Plus Usual Care</title>
          <description>Genetic testing for SLCO1B1*5 allele
Reporting for SLCO1B1*5 allele at randomization
Reporting for SLCO1B1*5 allele at randomization: Reporting of genetic test results to patient and provider at randomization
Genetic testing for SLCO1B1*5 allele: Blood test for SLCO1B1*5 allele</description>
        </group>
        <group group_id="E2">
          <title>Usual Care Only</title>
          <description>Genetic testing for SLCO1B1*5 allele
Reporting for SLCO1B1*5 allele at the end of study
Reporting for SLCO1B1*5 allele at the end: Usual care recommendations provided to patient and provider at randomization. Genotyping results provided at the end of study.
Genetic testing for SLCO1B1*5 allele: Blood test for SLCO1B1*5 allele</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, vomiting, abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver function testing abnormality</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Suspected MRSA bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Deepak Voora</name_or_title>
      <organization>Duke University</organization>
      <phone>919-668-1755</phone>
      <email>Deepak.vorra@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

